Epizyme Inc

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines.

We’re focused on identifying and developing the next generation of cancer medicines that target key epigenetic modulators and have spent the last decade developing a proven research platform to systematically identify and target key epigenetic targets that, when altered or dysregulated, can drive tumor cell proliferation and/or survival. The use of a proprietary CRISPR screening technology has allowed us to evaluate the role of over 600 epigenetic related targets in more than 400 cancer cell lines. We’ve observed that validated targets tend to cluster within certain epigenetic gene families enabling a broader gene family approach to drug discovery. The individual targets within these families are further credentialed based on their disease-related biology, “druggability,” potential for clinical development, commercial opportunity, and importantly, the medical need.

This platform has led to a large number of prioritized targets for which we have identified inhibitors through the application of our internal drug discovery engine often in conjunction with and our proprietary compound library. This privileged library has been extensively characterized within multiple epigenetic target families performing large cross-screens, providing starting points for rapid lead generation against new targets, as well as critical information about off-target activities.